OKYO Pharma's Urcosimod Phase 2 Data Accepted for Presentation at Prestigious ASCRS Meeting

summarizeSummary

OKYO Pharma announced that efficacy and safety data from its Phase 2 study of urcosimod for neuropathic corneal pain has been accepted for presentation at the 2026 ASCRS Annual Meeting, providing external validation for its lead candidate.

check_boxKey Events

• Phase 2 Data Accepted for ASCRS Presentation

  An abstract detailing efficacy and safety results from the proof-of-concept Phase 2 study of urcosimod for neuropathic corneal pain (NCP) has been accepted for presentation at the prestigious 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting.

• Validation of Lead Candidate

  This acceptance, following a competitive review process, provides external validation for urcosimod's potential as a novel therapeutic for NCP, building on previously announced positive efficacy signals.

• Supports Upcoming Phase 2b/3 Trial

  The presentation will share these results with leading ophthalmologists, advancing development efforts towards a planned 150-patient Phase 2b/3 multiple-dose study of urcosimod for NCP, expected to initiate in the first half of 2026, following recent FDA alignment on trial design on January 28, 2026.

auto_awesomeAnalysis

OKYO Pharma's announcement of its urcosimod Phase 2 data acceptance for presentation at the ASCRS Annual Meeting provides significant external validation for its lead candidate. This recognition from a prestigious scientific body reinforces the positive efficacy and safety signals previously observed in the proof-of-concept study for neuropathic corneal pain. The presentation will increase visibility among key ophthalmologists and supports the company's strategic path towards initiating a larger Phase 2b/3 trial in the first half of 2026, a plan recently aligned with the FDA. This event builds positive momentum for the company's clinical development efforts.